HOLUBIAK MYRON Z 4
4 · CITIUS ONCOLOGY, INC. · Filed Sep 23, 2025
Insider Transaction Report
Form 4
HOLUBIAK MYRON Z
DirectorSecretary
Transactions
- Award
Common Stock
2025-09-19+850,000→ 850,000 total - Award
Common Stock
2025-09-19+100,000→ 100,000 total(indirect: See footnote)
Holdings
- 1,500,000
Stock Option (Right to Buy)
Exercise: $2.15Exp: 2033-07-05→ Common Stock (1,500,000 underlying) - 300,000
Stock Option (Right to Buy)
Exercise: $1.07Exp: 2034-12-12→ Common Stock (300,000 underlying) - 50,000(indirect: See footnote)
Stock Option (Right to Buy)
Exercise: $1.07Exp: 2034-12-12→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- [F2]Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
- [F3]These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- [F4]These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
- [F5]These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.